-
Product Insights
![]()
Peripheral Embolic Protection Devices Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Peripheral Embolic Protection Devices Pipeline Market Report Overview Embolic Protection Device(s) EPDs are used to capture and remove plaque debris that are dislodged during interventional procedures. Peripheral Embolic Protection Devices (EPDs) used in the lower extremity, carotid and renal arteries have been accounted for. One unit refers to one EPD. Carotid Embolic Protection Devices and Lower Extremity Embolic Protection Devices are tracked under this segment. Angioplasty: Angioplasty is a minimally invasive interventional procedure that is used to surgically unblock an...
-
Thematic Analysis
![]()
3D Printing – Thematic Intelligence
3D Printing Report Overview The 3D printing or additive manufacturing (AM) industry is anticipated to record strong growth during 2021-2030. 3D printing grabbed headlines during the COVID-19 pandemic for providing replacement parts and alleviating supply chain disruption. However, the slow post-COVID-19 recovery, coupled with the economic shock of the Russia-Ukraine war, has been challenging for the 3D printing industry to navigate. Moreover, the macroeconomic and environmental forces shaping the manufacturing landscape will have just as significant an impact on the...
-
Analyst Opinions
![]()
Towards Next Generation Asset Class – Can NFTs Outlive Hype as New Gold of Crypto Economy?
The NFT market grew by more than 2,000% to surpass $2 billion in Q1 2021 sales. It sprung to $2.5 billion by the first half of 2021. NFTs maintained more than 1% of the Ethereum and 0.17% of the Bitcoin market capitalization in 2020. NFTs unfold a new frontier in the use case of blockchain technology to monetize digital creative content. Slowly but surely, they are proving to be bigger than an art fad by finding real-time use cases in...
-
Sector Analysis
![]()
Head and Neck Squamous Cell Carcinoma – Opportunity Analysis and Forecast to 2026
The head and neck (HNC) cancer market is expected to experience significant growth between 2016 and 2026 within the seven major markets (US, France, Germany, Italy, Spain, UK and Japan). The main growth drivers will be attributed to the incorporation of immune-checkpoint inhibitors into the first-line recurrent/metastatic and locally-advanced disease treatment paradigms. Due to the high cost of immunotherapy regimens, this is expected to cause large growth within the head and neck cancer market. Up until the approvals of Opdivo...
-
Product Insights
![]()
Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Non-Small Cell Lung Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Small Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
![]()
OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025
Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission,...
-
Sector Analysis
![]()
OpportunityAnalyzer: Bladder Cancer – Opportunity Analysis and Forecasts to 2025
The bladder cancer market in the seven major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, and Japan) has remained largely unchanged in the past 10-20 years. However, significant expansion is expected starting in 2016, with the introduction of several new therapies that are projected to fuel market growth. In addition, bladder cancer has a robust early-stage pipeline that will contribute to market growth during the forecast period. Currently, the bladder cancer market is dominated by generic chemotherapy and immunotherapy....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.